263 related articles for article (PubMed ID: 18403654)
1. Schizophrenia: moving beyond monoamine antagonists.
Conn PJ; Tamminga C; Schoepp DD; Lindsley C
Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
[TBL] [Abstract][Full Text] [Related]
3. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics in the early stage of development.
Biedermann F; Fleischhacker WW
Curr Opin Psychiatry; 2009 May; 22(3):326-30. PubMed ID: 19346948
[TBL] [Abstract][Full Text] [Related]
5. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
6. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
Nikam SS; Awasthi AK
Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
[TBL] [Abstract][Full Text] [Related]
7. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Newman-Tancredi A; Cussac D; Depoortere R
Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474
[TBL] [Abstract][Full Text] [Related]
8. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
Miyamoto S; Duncan GE; Marx CE; Lieberman JA
Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic mechanisms in psychotic disorders.
McKinzie DL; Bymaster FP
Handb Exp Pharmacol; 2012; (213):233-65. PubMed ID: 23027418
[TBL] [Abstract][Full Text] [Related]
10. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
Marek GJ
Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic approaches in the development of novel antipsychotics.
Jones CA; McCreary AC
Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
Bolbecker AR; Shekhar A
Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
[TBL] [Abstract][Full Text] [Related]
13. Role of the cholinergic system in the pathology and treatment of schizophrenia.
Scarr E; Dean B
Expert Rev Neurother; 2009 Jan; 9(1):73-86. PubMed ID: 19102670
[TBL] [Abstract][Full Text] [Related]
14. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
Millan MJ; Brocco M
Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
[TBL] [Abstract][Full Text] [Related]
15. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
16. Cholinergic aspects of schizophrenia.
Tandon R
Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
[TBL] [Abstract][Full Text] [Related]
17. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
Teal LB; Gould RW; Felts AS; Jones CK
Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
Scarr E; Dean B
J Neurochem; 2008 Dec; 107(5):1188-95. PubMed ID: 18957051
[TBL] [Abstract][Full Text] [Related]
19. Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome.
Barak S
Behav Brain Res; 2009 Dec; 204(2):335-51. PubMed ID: 19376161
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic drug action: targets for drug discovery with neurochemical imaging.
Stone JM; Pilowsky LS
Expert Rev Neurother; 2006 Jan; 6(1):57-64. PubMed ID: 16466312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
